Search for Clinical Trial Results
Leiomyosarcoma - 29 Studies Found
| Status | Study |
| Active, not recruiting |
Study Name: A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Condition: Advanced or Metastatic Liposarcoma or Leiomyosarcoma Date: 2012-08-06 Interventions:
|
| Completed |
Study Name: Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma Condition:
Date: 2006-01-24 Interventions: Drug: gemcitabine, docetaxel, doxorubicin Cycles = 28 days |
| Active, not recruiting |
Study Name: Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma Condition:
Date: 2006-12-19 Interventions: Drug: Letrozole 2.5 mg Tablet By Mouth Daily for 12 Weeks. |
| Completed |
Study Name: Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Condition:
Date: 2006-09-19 Interventions: Drug: sunitinib malate Given orally Other Names: |
| Completed |
Study Name: Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Condition:
|
| Active, not recruiting |
Study Name: Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Condition:
|
| Recruiting |
Study Name: Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Condition:
Interventions: |
| Completed |
Study Name: Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus Condition:
Date: 2008-01-31 Interventions: Drug: Docetaxel plus Gemcitabine Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV |
| Not yet recruiting |
Study Name: Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Condition:
Date: 2017-03-01 Interventions:
|
| Completed |
Study Name: Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Condition:
|